Aortic stenosis (AS) is one of the most common valvular diseases encountered in clinical practice. Current guidelines recommend aortic valve replacement (AVR) when the aortic valve is severely stenotic and the patient is symptomatic; however, a substantial proportion of patients with severe AS are asymptomatic at the time of first diagnosis. Although specific morphological valve features, exercise testing, stress imaging, and biomarkers can help to identify patients with asymptomatic severe AS who may benefit from early AVR, the optimal management of these patients remains uncertain and controversial. The current report presents a comprehensive review of the natural history and the diagnostic evaluation of asymptomatic patients with severe AS, and is followed by a meta-analysis from reported studies comparing an early AVR strategy to active surveillance, with an emphasis on the level of evidence substantiating the current guideline recommendations. Finally, perspectives on directions for future investigation are discussed.
evaluation of asymptomatic patients with severe AS, and is followed by a meta-analysis from reported studies comparing an early AVR strategy to active surveillance, with an emphasis on the level of evidence substantiating the current guideline recommendations. Finally, perspectives on directions for future investigation are discussed. A ortic stenosis (AS) affects w5% of adults above the age of 65 years (1) . It is one of the most common valvular diseases in developed countries, and its prevalence is projected to increase over the next decade with an aging population (2, 3) . Untreated, symptomatic severe AS is associated with a dismal prognosis (4) (5) (6) , with as many as half of patients dying within 1 or 2 years (7) (8) (9) . Aortic valve replacement (AVR), either surgical or via a transcatheter approach, is the only treatment shown to improve survival (10) (11) (12) (13) (14) . Current guidelines recommend surgical AVR (SAVR) as a Class I indication for appropriate patients with severe symptomatic AS.
Transcatheter AVR (TAVR) is recommended with a Class I indication for severe symptomatic AS patients who are not candidates for SAVR and with a Class IIa recommendation as an alternative to SAVR in "highrisk" AS patients (15, 16) .
As many as 50% of patients with severe AS report no symptoms at the time of diagnosis (17) (18) (19) . The optimal timing of intervention for these patients is uncertain and controversial (17, (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . Although current guidelines recommend AVR for selected patients with asymptomatic severe AS ( symptoms is w1% to 1.5% per year. Given the current low periprocedural mortality rates for isolated SAVR and TAVR, earlier intervention has been increasingly advocated (11) (12) (13) (14) 18, 19, (25) (26) (27) (28) (29) (30) (31) ; however, the current conservative strategy of watchful waiting in patients with asymptomatic severe AS has never been compared with early AVR in a randomized trial.
The present report will review the natural history of asymptomatic severe AS and subsequently summarize the potential roles of exercise testing, biomarker assessment, and imaging to guide the optimal timing of AVR.
A meta-analysis from reported studies comparing an AVR strategy with a watchful waiting approach will also be presented. (i.e., hypotension or <20 mm Hg increase). These findings are derived from studies of approximately 100 patients (34, (36) (37) (38) (39) . These studies show that patients who experience any of the criteria mentioned earlier are more likely over time to develop symptoms, undergo AVR, or die than patients who do not display these criteria; however, the number of deaths in these studies is low, and it is not clear whether these patients would benefit from early AVR (before they progress to stage D). Similarly, although patients with peak aortic velocity $5 m/s or $5.5 m/s have an increased event rate, the events are usually development of symptoms and not sudden cardiac death while asymptomatic (25, 35, 40) .
Whether the low rate of sudden death would be reduced with early AVR is unknown, an important consideration given the morbidity and cost of the procedure in an asymptomatic population.
NATURAL COURSE OF ASYMPTOMATIC SEVERE AS
Patients with asymptomatic severe AS have a better prognosis than those with symptomatic severe AS (40); however, 5 years after receiving the diagnosis, approximately two-thirds of conservatively managed patients with asymptomatic AS will develop symptoms, and 75% will have either died or undergone AVR (18) .
The rate of hemodynamic progression of severe AS is variable and unpredictable. The average annual increase in aortic jet velocity has been estimated to be 0.3 m/s, and the annual decrease in AVA has been estimated at 0.1 cm 2 (32) . Several predictors of rapid hemodynamic progression have been reported, including smoking, dyslipidemia, male sex, diabetes mellitus, hypertension, chronic kidney disease, and coronary artery disease (41) . To what extent these factors contribute to AS progression is unknown. The aortic valve calcium load is the most powerful predictor of rapid stenosis progression (42) .
In patients with asymptomatic severe AS, 1-year and 5-year survival rates have been reported to range from 67% to 97% and 38% to 83%, respectively (19, 26, 33, 40, 43) . A recent retrospective analysis of 1,517 conservatively treated patients with asymptomatic severe AS by Taniguchi et al. (26) , the largest study to date, reported 1-year and 5-year survival rates of 92.8% and 73.6%, respectively. However, many patients who died did so after first developing symptoms and were not referred for AVR. The risk of dying in asymptomatic patients is directly related to the severity of AS and its rate of progression (18, 32) .
Patients with limiting symptoms on exercise testing are significantly more likely to develop spontaneous symptoms or die than those without exercise-limiting symptoms (39, 44) . Other reported predictors of death or subsequent need for AVR include age, chronic heart failure, chronic renal insufficiency, and inactivity (18, 32) . Beta-blocker use and higher LVEF have been associated with better prognosis (19) . Although statin use in patients with AS has been shown to decrease the rates of ischemic cardiovascular events (mainly the need for coronary artery bypass graft), its role in preventing major clinical valve-related outcomes (such as the need for AVR) has never been demonstrated (45) .
DEVELOPMENT OF SYMPTOMS AND THE NEED FOR AVR
The median time to symptom onset, AVR, or death has ranged between 1 and 4 years ( were asymptomatic at the last examination performed within 1 yr before death, and the estimated actuarial 6-yr rate of sudden death not preceded by symptoms was 10%. Propensity score matched paired comparison (n ¼ 57 pairs): all-cause mortality was significantly lower in the early AVR group than in the medical treatment group (HR: 0.14; 95% CI: 0.03-0.60; p ¼ 0.008). 6-yr survival and cardiac mortality-free survival rates were 98% and 100% in the early surgery group and 68% and 76% in the medical treatment group respectively, both p < 0.001. The survival rates free of cardiac mortality in the conventional treatment group were 91% at 2 yrs, 83% at 4 yrs, and 76% at 6 yrs. Continued on the next page Généreux et al.
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Asymptomatic Severe Aortic Stenosis 
SUDDEN DEATH IN ASYMPTOMATIC SEVERE AS
The risk of sudden death has been reported to be approximately 1% per year in clinically asymptomatic patients with severe AS (17, 25, (32) (33) (34) 38, 39, 43, (47) (48) (49) (50) (51) (52) (53) Table 3) .
V max is one of the strongest independent echocardiographic predictors of adverse cardiovascular events in patients with AS (17, 18, 25, 32, 34, 35, 40, (48) (49) (50) (51) (52) (53) (54) (55) (56) . Echocardiography can also provide semiquantitative Tables 1 and 2 .
assessment of the degree of valve calcification and can identify anatomic valve abnormalities, including bicuspid morphology (Table 3) . 
EXERCISE TESTING IN ASYMPTOMATIC SEVERE AS
The incidence of an abnormal stress test varies, depending of the severity of AS; for patients with asymptomatic severe AS undergoing stress testing, the incidence of abnormal stress test has ranged between 28% and 67%, with a pooled average of 49% ( Continued on the next page
abnormal blood pressure response or ST-segment changes; however, these studies were small and heterogeneous, and the optimal criteria for a positive test remain unknown (34, (36) (37) (38) (39) Tables 2 and 3. of 2 relatively small studies. Maréchaux et al. (33) performed echocardiography at rest and during ex- mm Hg) at peak exercise also has incremental prognostic value. Other studies that evaluated stress echocardiography in patients with asymptomatic severe AS are summarized in Table 6 .
CT AND CMR IMAGING IN ASYMPTOMATIC AS
CT and CMR imaging are increasingly used in patients with AS. Both techniques provide detailed information of valve, aortic root, and aortic morphology and are useful for pre-procedural assessment before SAVR or TAVR.
Multislice CT has the capability of quantifying the degree and severity of aortic valve calcification. The calcium score correlates strongly with actual aortic valve calcium weight as measured post-mortem, with the echocardiographic hemodynamic severity of AS Decreased LVEF at exercise was associated with development of CV death or spontaneous symptoms at follow-up.
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BIOMARKERS IN ASYMPTOMATIC SEVERE AS
The ESC/EACTS guidelines note that AVR may be 2. Surgical ineligibility (due to frailty, for example) is one of the strongest correlates of mortality, a risk factor that is typically not captured in administrative databases and the pooled studies. Table 4) . This may not be surprising, as these studies varied in regard to inclusion criteria and even the definition of severe AS. Outcomes beyond mortality were variably reported and not adjudicated.
Given these issues, a large-scale, prospective, randomized clinical trial to evaluate whether routine SAVR or TAVR improves prognosis in patients with asymptomatic severe AS merits strong consideration before adoption of such a strategy can be recommended (27, 28) . 
